Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Change in Cash (2016 - 2025)

Kiora Pharmaceuticals' Change in Cash history spans 11 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 272.76% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $4.9 million, up 266.73%, while the annual FY2025 figure was $4.9 million, 266.73% up from the prior year.
  • Change in Cash reached $3.2 million in Q4 2025 per KPRX's latest filing, down from $4.5 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $28.8 million in Q1 2024 to a low of -$24.7 million in Q2 2024.
  • Average Change in Cash over 5 years is $386411.6, with a median of -$1.8 million recorded in 2024.
  • The largest YoY upside for Change in Cash was 1215.57% in 2024 against a maximum downside of 645.81% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$3.3 million in 2021, then increased by 14.29% to -$2.8 million in 2022, then dropped by 5.68% to -$2.9 million in 2023, then skyrocketed by 37.36% to -$1.8 million in 2024, then surged by 272.76% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Change in Cash are $3.2 million (Q4 2025), $4.5 million (Q3 2025), and -$2.7 million (Q2 2025).